Inventor · disambiguated record
Jonathan Davis
Also filed as: DAVIS JONATHAN · DAVIS JONATHAN H · DAVIS JONATHAN HARRY
30 granted patents·14 pending applications·345 citations·filing 2006–2024
97Inventor score
Files withBRISTOL MYERS SQUIBB CO30MERCK PATENT GMBH6CAMPHAUSEN RAY2INVENRA INC2CANCER RESEARCH TECH LTD1
Top patents by PatentIndex Score
44 records- 0197US9505848B2Engineered heterodimeric protein domainsMERCK PATENT GMBH·Filed 2014·Granted Nov 29, 2016·44 cites·7 claims
- 0297US8420098B2Fibronectin based scaffold domain proteins that bind to PCSK9CAMPHAUSEN RAY·Filed 2011·Granted Apr 16, 2013·86 cites·8 claims
- 0396US9522951B2Fibronectin binding domains with reduced immunogenicityBRISTOL MYERS SQUIBB CO·Filed 2012·Granted Dec 20, 2016·18 cites·20 claims
- 0496US9416170B2Fibronectin binding domains with reduced immunogenicityBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Aug 16, 2016·16 cites·45 claims
- 0596US8871912B2Engineered heterodimeric protein domainsDAVIS JONATHAN H·Filed 2007·Granted Oct 28, 2014·84 cites·5 claims
- 0694US10787494B2Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of useBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Sep 29, 2020·8 cites·8 claims
- 0794US9469676B2Fc fusion proteins comprising novel linkers or arrangementsCAMPHAUSEN RAY·Filed 2012·Granted Oct 18, 2016·19 cites·7 claims
- 0893US10604556B2Fibronectin binding domains with reduced immunogenicityBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Mar 31, 2020·5 cites·20 claims
- 0993US9765132B2Fibronectin binding domains with reduced immunogenicityBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Sep 19, 2017·9 cites·46 claims
- 1092US11359000B2Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of useBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Jun 14, 2022·5 cites·23 claims
- 1192US9856309B2Fibronectin based scaffold domain proteins that bind PCSK9BRISTOL MYERS SQUIBB CO·Filed 2015·Granted Jan 2, 2018·10 cites·16 claims
- 1291US10947297B2Fibronectin based scaffold domain proteins that bind PCSK9BRISTOL MYERS SQUIBB CO·Filed 2017·Granted Mar 16, 2021·5 cites·19 claims
- 1390US10442851B2Serum albumin-binding fibronectin type III domainsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Oct 15, 2019·5 cites·12 claims
- 1490US9234027B2Fibronectin based scaffold domain proteins that bind PCSK9BRISTOL MYERS SQUIBB CO·Filed 2013·Granted Jan 12, 2016·10 cites·22 claims
- 1588US10214579B2Fc fusion proteins comprising novel linkers or arrangementsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Feb 26, 2019·3 cites·9 claims
- 1687US10464995B2Fibronectin binding domains with reduced immunogenicityBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Nov 5, 2019·2 cites·17 claims
- 1786US11203630B2Serum albumin-binding fibronectin type III domainsBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Dec 21, 2021·2 cites·9 claims
- 1886US8691952B2Anti-CD19 antibodies with reduced immunogenicitySUPER MICHAEL·Filed 2006·Granted Apr 8, 2014·8 cites·32 claims
- 1986US2025179140A1Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of useBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 2086US2024239870A1Fibronectin based scaffold domain proteins that bind pcsk9BRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 2185US11408093B2Fibronectin binding domains with reduced immunogenicityBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Aug 9, 2022·1 cites·20 claims
- 2284US2023183885A1Fibronectin binding domains with reduced immunogenicityBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 2382US2022275535A1Fibronectin binding domains with reduced immunogenicityBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 2481US8957195B2Anti-CD19 antibodies with reduced immunogenicityMERCK PATENT GMBH·Filed 2014·Granted Feb 17, 2015·3 cites·32 claims
- 2579US12202872B2Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of useBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Jan 21, 2025·0 cites·15 claims
- 2678US11279751B2Fibronectin binding domains with reduced immunogenicityBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 22, 2022·0 cites·20 claims
- 2776US11858979B2Fibronectin based scaffold domain proteins that bind PCSK9BRISTOL MYERS SQUIBB CO·Filed 2021·Granted Jan 2, 2024·0 cites·10 claims
- 2874US2023242617A1Fibronectin based scaffold proteinsBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 2972US11447538B2Fibronectin based scaffold proteinsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Sep 20, 2022·0 cites·8 claims
- 3072US10072092B2Methods of use of anti-CD19 antibodies with reduced immunogenicityMERCK PATENT GMBH·Filed 2015·Granted Sep 11, 2018·1 cites·17 claims
- 3172US2021122805A1Fc FUSION PROTEINS COMPRISING NOVEL LINKERS OR ARRANGEMENTSBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 3270US2019248872A1Fc FUSION PROTEINS COMPRISING NOVEL LINKERS OR ARRANGEMENTSBRISTOL MYERS SQUIBB CO·Filed 2019·Application pending·0 cites
- 3369US11208496B2Anti-CD19 antibodies with reduced immunogenicityCANCER RESEARCH TECH LTD·Filed 2018·Granted Dec 28, 2021·0 cites·1 claims
- 3468US10407490B2Polypeptides targeting HIV fusionBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Sep 10, 2019·1 cites·12 claims
- 3567US2025353910A1Multispecific binding agents that target b7h3 and gd2 and uses thereofINVENRA INC·Filed 2024·Application pending·0 cites
- 3666US2023407331A1Miniaturized dystrophins having spectrin fusion domains and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 3766US2019211079A1Engineered heterodimeric protein domainsMERCK PATENT GMBH·Filed 2018·Application pending·0 cites
- 3864US12312418B2Orthogonal mutations for heterodimerizationINVENRA INC·Filed 2021·Granted May 27, 2025·0 cites·1 claims
- 3963US11535868B2Miniaturized dystrophins having spectrin fusion domains and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Dec 27, 2022·0 cites·26 claims
- 4061US2017145078A1Engineered heterodimeric protein domainsMERCK PATENT GMBH·Filed 2016·Application pending·0 cites
- 4161US2015361159A1Fibronectin based scaffold proteinsBRISTOL MYERS SQUIBB CO·Filed 2014·Application pending·0 cites
- 4256US11155602B2Polypeptides targeting HIV fusionVIIV HEALTHCARE NO 5 LTD·Filed 2019·Granted Oct 26, 2021·0 cites·7 claims
- 4353US2010029499A1Artificial Protein ScaffoldsMERCK PATENT GMBH·Filed 2009·Application pending·0 cites
- 4446US2021403947A1Miniaturized dystrophins and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jonathan Davis files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →